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Abstract
Background: The current study evaluated the effects of a combination of flunarizine (flu) a calcium channel blocker, glibenclamide (Glib), a KATP channels blocker and B
vitamins (B com) on the behavioral symptoms of 6-hydroxydopamine (6-OHDA)-induced model of Parkinson disease to examine the synergistic antiparkinsonian effects
of the drugs and supplements. Also the level of malondialdehyde (MDA) was measured in blood and brain suspensions to find probable neuroprotective mechanism of
these materials.
Methods: 6-OHDA was injected into striatum of rats by stereotaxic surgery. Pretreatment with flu, Glib and B com was started before the surgery and continued to three
weeks after the surgery. Development and severity of Parkinson disease were evaluated by the conventional behavioral tests. MDA values were measured spectrophoto-
metrically, using thiobarbituric acid test and the MDA standard curve.
Results: Pretreatment with a combination of flu, Glib and B com ameliorated the behavioral symptoms of Parkinson disease. The effect of the combination was signifi-
cantly more potent than those of flu, Glib or B com, solely. Pretreatment with the combination or using only Glib or B com separately, reduced the level of MDA in blood
and brain, significantly. However, the effect of the combination was significantly more potent than those of Glib or B com, solely.
Conclusions: Since the severity of the behavioral symptoms in the 6-OHDA-induced model of Parkinson disease reflects the degree of the lesion in substantia nigra (SN)
dopaminergic neurons, it is suggested that using the combination had neuroprotective effects. The obtained data suggest a synergistic neuroprotective and antiparkin-
sonian effect for flu, Glib and B com. At least, a part of this effect was mediated through inhibition of oxidative stress.
Keywords: 6-Hydroxydopamine, Flunarizine, Glibenclamide: B Vitamins, Behavioral Symptoms, Malondialdehyde
1. Background
Parkinson disease (PD) is a chronic and progressive
neurodegenerative disorder affecting approximately 1.5
million individuals in the US alone and with the extension
of life expectancy this number is expected to rise remark-
ably within the next decades.
The pathological hallmark of PD is the loss of the ni-
grostriatal dopaminergic (DA) neurons. The cell bodies of
these neurons are in the compact part of substantia ni-
gra (SNpc), and they project primarily to the putamen. At
the onset of symptoms, putamen dopamine is depleted by
80%, and 60% of SNpc dopaminergic neurons are already
lost (1-4).
Current PD medications treat symptoms; none of them
halt or retard DA neuron degeneration. Therefore, the cur-
rent research aimed to prevent DA neurons degeneration.
Flunarizine (flu) is a wide spectrum calcium channel
blocker which blocks the T-, L- and N-type calcium channels
(5, 6), and also Na+ channels and prevents the overloading
of the cell with Ca2+ under pathological and ischemic con-
ditions (7). Neuroprotective effect of this drug is wildly in-
vestigated and it is shown that flu has cytoprotectant ac-
tions in neuronal cultures (5, 8), chromaffin cell cultures
(9), hippocampal slices (10) and in animal models of stroke
(11).
ATP-sensitive potassium (KATP) channels are suggested
as a potential pharmacotherapeutic target for neuropro-
tection in some neurodegenerative diseases, including PD
(12, 13). They are considered to play an important role in
maintaining the membrane potential and mitochondrial
matrix volume during ATP decline (12, 14). Studies showed
that DA neurons in the SNpc have a high density of KATP
channels (15). Glibenclamide (Glib) is a second genera-
tion sulfonylurea; it exhibits an inhibitory effect on surface
and mitochondrial KATP channels (16). Several authors re-
ported that Glib provides neuroprotective effects (17-21).
Also, evidence shows that B vitamins (B com) pro-
vide neuroprotective effects, probably through preven-
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tion of mitochondrial dysfunction and inhibition of ox-
idative stress (22). Previously, it was shown that B vita-
mins can reduce severity of behavioral symptoms in 6-
hydroxydopamine (6-OHDA)-induced model of Parkinson
disease (23, 24).
The present study evaluated the effect of a combina-
tion of Glib, flu and B com on the behavioral symptoms of
6-OHDA–induced model of Parkinson disease in rats. It was
hypothesized that each of these materials provides neuro-
protective effects by mechanism(s) which differ from the
mechanisms of the other ones. Therefore, it was supposed
that they have synergistic antiparkinsonian effect. To find
probable neuroprotective mechanism of these materials,
the study measured the concentration of Malondialde-
hyde (MDA), which is a biomarker of lipid peroxidation
and oxidative stress both in the serum and in the midbrain
portion of brain. The study focused on oxidative stress
since 6-OHDA selectively destroys catecholamine neurons
by production of reactive oxygen species (ROS). Also, many
studies suggest that oxidative stress plays an important
role in the events leading to degeneration of DA neurons
in humans with PD (1-4).
2. Methods
2.1. Animals and Experimental Groups
The current study was an original/basic scientific re-
search performed in the cellular and molecular research
center of Qazvin University of Medical Sciences, Qazvin,
Iran. All procedures carried out throughout this study
were according to the guidelines of animal experiments of
research council at Qazvin University of Medical Sciences.
Adult male Wistar rats (Razi Institute, Karaj, Iran), weigh-
ing 250 - 300 g at the beginning of the study were housed in
large cages (38× 59× 20 cm) at a temperature-controlled
colony room under light/dark cycle with free access to tap
water and standard food.
Animals were divided into six experimental groups as
follows: control (con, n = 9) which did not receive any pre-
treatment; vehicle (veh, n = 10) which received ethanol as
the solvent of flu and Glib; B com (n = 9) which received
a combination of all of B vitamins five times higher than
that in normal MEM (minimum essential medium); F (n
= 9) which received flu 5 mg/kg; G (n = 9) which received
Glib 5 mg/kg; and F+G+B com (n = 10) which received a
combination of flu and Glib 5 mg/kg and also B com. Ad-
ditional B vitamins were dissolved in drinking water as de-
scribed before (24). Ethanol, Glib and flu were daily ad-
ministrated, intraperitoneally. In addition, results of an-
other group of rats (n = 8) referred to healthy rats, were also
used to analyze data obtained from rotarod test. Healthy
rats were intact rats which did not receive 6-OHDA or any
other treatments. All of B vitamins, flu, Glib, 6-OHDA and
apomorphine were purchased from SIGMA-ALDRICH Com-
pany (Germany).
2.2. Experimental Design
All animals (except healthy group) received 6-OHDA
through stereotaxic surgery. All pretreatments were
started a few hours before 6-OHDA injection and con-
tinued up to three weeks after the surgery (Figure 1).
Apomorphine-induced rotational test and elevated body
swing test (EBST) were performed during the second,
fourth and eighth weeks post-surgery. Rotarod test was
performed in the sixth week post-surgery. Blood sampling
and serum MDA assay were performed after rotarod test.
After performing the behavioral tests, animals were de-
capitated and MDA concentration in the brain tissues was
measured.
2.3. Surgical Procedures
After anesthetization of rats with intraperitoneal injec-
tion of a solution containing ketamine (100 mg/kg) and
xylazine (5 mg/kg), 4 µL of 6-OHDA (4 µg/µL) dissolved
in isotonic NaCl solution containing 0.2 mg/mL of ascor-
bic acid was injected into the four sites at right stria-
tum using stereotaxic apparatus (Stoelting, USA) through
a 10-µL Hamilton syringe. Coordinates for injections were
anterior/posterior (AP): 1.5 mm, laterality (L): -2.5 mm,
dorsoventral (DV): -6 mm and AP: 0.8 mm, L: -3 mm, DV: -
6 mm, and AP: 0.1 mm, L: -3.2 mm, DV: -6 mm and AP: -0.5
mm, L: -3.6 mm and DV: -6 mm. AP and L were measured
from bregma and DV from the surface of skull according
to the atlas of Paxinos and Watson (25).
2.4. Behavioral Testing
2.4.1. Apomorphine-Induced Rotational Test
Apomorphine-induced rotational test was imple-
mented according to Fujita et al., (26). Animals were
first habituated for 5 minutes and then apomorphine
hydrochloride (0.5 mg/ kg, IP, dissolved in saline) was
injected. One minute later, the number of full rotations
was counted for one hour in a cylindrical container (with
diameter of 28 and height of 38 cm). Contralateral and
ipsilateral rotations (away and toward the lesioned side,
respectively) were counted as positive and negative scores
and the net number of rotations defined as the positive
scores minus the negative ones.
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Figure 1. Time schedule for the experiments
Rotational Test & EBST
Rotational Test & EBST
Rotational Test & EBST
Rotarod Test 
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MDA Measurement
0                        14                      28                                                     56
6-OHDA Injection
Brain Suspension
MDA Measurement
Animals were tested by apomorphine-induced rotational test and elevated body swing test (EBST) three times: in the second, fourth and eighth weeks after 6-OHDA injection.
Rotarod rod test, blood sampling and measuring the level of MDA were performed in the sixth week post-surgery. Preparation of the brain suspension and its MDA assay were
performed in the eighth week post-surgery. All pretreatments were started before 6-OHDA injection and continued up to three weeks after that (black arrow). Numbers show
the days after 6-OHDA injection.
2.4.2. Elevated Body Swing Test
The elevated body swimming test (EBST) was per-
formed according to the previously described method (27).
Animal was allowed to habituate for 10 minutes in a cylin-
drical container, to attain a neutral position, defined as
having all four paws on the floor. Then, the animal was held
at a position two cm from the base of its tail. After that,
the animal was lifted up 2 cm above the surface. The ani-
mal was held in the vertical axis, defined as no deviation of
more than 100 to either side. Whenever the animal moved
its head out of the vertical axis to either side a swing was
recorded. For the next swing to be counted, the animal
should have returned to the vertical position. Swings were
counted for a period of one minute. One observer held
the test session time and also determined and recorded
the direction and the frequency of swings, while another
observer held the rat. All tests were conducted blind to
the groups. Biased swing behavior was calculated as fol-
lows: L/ (L + R) (%) for left-biased swings and R/(R + L) (%)
for right-biased swings (L = amount of left-biased swings,
R = amount of right-biased swings).
2.4.3. Rotarod Test
The study used rotarod apparatus (M.T6800, Borj
Sanat, Iran) to determine the motor performance and the
ability of rats to improve motor skill with training. Ro-
tarod test was performed at three consecutive days and two
sessions a day. Each session lasted a maximum of 200 sec-
onds, during which the rotating rod underwent a linear ac-
celeration of 5 to 40 rpm over the first 120 seconds of the
trial and remained at maximum speed for the remaining
200 seconds. Animals were scored for their latency (in sec-
onds) to fall (height 30 cm) for each trial. Rats were given
a minimum rest of 30 minutes between trials to avoid fa-
tigue. Rotarod data were expressed as the area under the
curve (AUC), which was computed according to the follow-
ing formula:
AUC= time on the rod (s)× [time on the rod(s)×0.44/2]
where 0.44 is the acceleration speed per second.
2.5. Blood Sampling and Preparing Brain Suspension
Venous blood samples were collected from the animal
tails into a 2 mL microtube using a scalp vein; while the an-
imals were restricted within a restrainer. Bloods were al-
lowed to clot and sera were separated using centrifugation
at 5000 rpm (Eppendorf 5415D) for 5 minutes and stored at
-80°C until MDA measurement.
To prepare brain suspension, animals were decapi-
tated under diethyl deep anesthesia and the brains were
removed immediately. Then the midbrain portion of brain
was isolated, washed with normal saline, and sonicated in
cooled KCl solution (1.5%) to provide a suspension. Brain
suspensions were stored at -80°C until MDA measurement.
2.6. MDAMeasurement
MDA values were measured spectrophotometrically by
the method described by Albro et al. (28), using thiobar-
bituric acid (TBA) test and MDA standard curve. 1,1,3,3-
tetramethoxypropane was used as standard. MDA reacts
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with TBA to produce a pink colored solution with the max-
imum absorbance at 532 nm. The results were expressed as
µM/L (for serum) and µM/g (for brain suspension).
2.7. Statistical Analysis
All data were presented as the mean± SE. Data on be-
havioral tests and MDA measurements were first analyzed
by Kolmogorov-Smirnov test to assess the normality of the
data. Since distribution was not normal, data were ana-
lyzed by Kruskall–Wallis nonparametric ANOVA followed
by a two-tailed Mann–Whitney U test. A P value≤ 0.05 was
considered statistically significant.
3. Results
3.1. Rotational Behavior
All experimental groups showed asymmetrical (con-
tralateral to lesioned side) rotations in response to apo-
morphine, indicating that none of the pretreatments
could prevent the development of 6-OHDA-induced model
of Parkinson disease. However, as displayed in Figure 2,
pretreatments significantly reduced severity of asymmet-
rical rotations. The most significant effect was observed in
F + G + B com group. In this group and in all rotational
tests, the number of net contralateral rotations was signif-
icantly less than those of veh or con groups (P < 0.05 and P
< 0.01, respectively). Severity of rotational behavior in F + G
+ B group in the 2nd and 3rd post-surgery tests was signifi-
cantly less than those of F, G or B com groups. In these tests,
severity of rotational behavior in B com, F and G groups was
also significantly less than that of the veh group (P < 0.05).
3.2. Swinging Behavior
Figure 3 displays findings of EBST. Number of swings
varied from 1 to 8 and almost all of the 6-OHDA lesioned rats
showed net ipsilateral (to lesioned side) swings. However,
in B com and F + G + B com groups, the number of biased
swings to ipsilateral side was significantly less than that of
the veh group. In the third post-surgery test, the number of
biased swings in F + G + B com group was also significantly
less than that of the F group. In this test, the number of bi-
ased swings in the G group was also significantly less than
that of the veh group.
3.3. Rotarod Test
Figure 4 illustrates capability of motor learning of dif-
ferent experimental groups in the rotarod test. In healthy
rats, learning was complete and the performance in each
session was better than that of the previous session and
rats reached the maximum performance in sessions 4 to 6.
All groups of 6-OHDA treated rats also showed some degree
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Figure2. Apomorphine-induced net contralateral rotations of different experimen-
tal groups in the second (upper plot), fourth (middle plot) and eighth (lower plot)
weeks post-surgery; values are means± S.E of animals in each group. *, P < 0.05 and
**, P < 0.01 compared to veh group; s, P < 0.05 compared to B com and F groups;
Kruskall-Wallis nonparametric test followed by Mann-Whitney U test.
of motor learning, but there were not complete and signif-
icant differences between 6-OHDA treated rats and healthy
ones. No one of the 6-OHDA treated group of rats reached
the (normally expected) maximum performance, even in
the last session. Also, learning pattern was different and
the performance did not necessarily improve enough in
successive sessions. However, some of the pretreatments
had significant effects and improved learning of 6-OHDA
lesioned rats. The best improvement was observed in F +
G + B com and G groups. In these groups although step-
ping time on rotarod did not reach the maximum, learning
pattern was very similar to that of the healthy rats. Step-
ping time in these groups in sessions 4 - 6 was significantly
higher than that of the veh group (P < 0.01 and P < 0.001,
respectively). Also, in these sessions stepping time in F +
G + B com and G groups was significantly higher than that
of F or B com groups (P < 0.01). Pretreatments with B vita-
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Figure 3. Plots display results of the EBST in the second (upper plot), fourth (middle
plot) and eighth (lower plot) weeks post-surgery; 50% means that the number of
the left swings was equal to the number of right swings. Less than 50% means that
most of the swings were toward left (contralateral to lesion side) and more than 50%
means that most of the swings were toward right (ipsilateral to lesion side) side. *,
P < 0.05 and **, P < 0.01 compared to veh group; s, P < 0.05 compared to F group;
Kruskall-Wallis nonparametric test followed by Mann-Whitney U test.
mins increased stepping time in sessions 5 and 6, but pre-
treatment with flunarizine had no effect.
3.4. MDA Analysis
MDA concentrations were measured in the serum and
brain suspension of rats. In the control group, MDA con-
centrations in blood and brain tissue were 6.16±0.33µM/L
and 9.34± 0.85 µM/g, respectively. In vehicle group, these
concentrations were insignificantly higher than those of
the control group (Figure 5). In F + G + B com group, MDA
concentrations both in serum and brain tissue were signif-
icantly less than those of the veh and F groups (P < 0.01
and P < 0.001, respectively). Also, MDA concentrations in
F + G + B com group in serum and brain were significantly
less than those of the B com and G groups (P < 0.05 and
P < 0.01, respectively). Pretreatment with B com or Glib
also significantly decreased the level of MDA in brain tis-
sue, but not in serum (P < 0.05 and P < 0.01, respectively).
On the other hand, pretreatment with flu increased serum
concentration of MDA (P < 0.05).
4. Discussion
The current study provided evidence that a combina-
tion of flu, Glib and B com has antiparkinsonian effect in
the 6-OHDA animal model. This effect was significantly
more potent than that of antiparkinsonian effects induced
by flu or Glib or B com alone and indicating that flu, Glib
and B com had synergistic antiparkinsonian effect. The
study also measured MDA in the serum and midbrain por-
tion of the brain. MDA is a biomarker of lipid peroxidation
and oxidative stress. Pretreatment with Glib or B com or a
combination of flu, Glib and B com reduced MDA concen-
tration in brain. Again, using the combination was more
effective than Glib or B com alone. The combination signif-
icantly reduced serum MDA level. On the other hand, using
flunarizine significantly increased serum MDA level.
A large body of evidence shows a positive relationship
between nigral cell death and the severity of behavioral
symptoms in the 6-OHDA-induced model of Parkinson dis-
ease. Rotational test is the most valid test in the evalua-
tion of 6-OHDA-induced model of Parkinson disease (27,
29-31) and can discriminate partial and nearly complete
lesions of the SN [31], and the time spent on the rotating
rod in rotarod test, and inversely correlates with the cell
loss in the SN. Also, many studies confirmed that EBST is
a valuable behavioral test accurately measuring disorders
of dopamine-mediated motor function (27, 32, 33). Based
on the evidence, it is suggested that pretreatment with flu,
Glib, B com or a combination of them had neuroprotective
effect and reduced neurotoxic effect of 6-OHDA on the SN
dopaminergic neurons. Since the antiparkinsonian effect
of the combination was more than those of flu, Glib or B
com alone, it is suggested that these pretreatments have
synergistic neuroprotective effects.
Previously, authors reported that B com has neuropro-
tective effect against 6-OHDA-induced neurotoxicity (24).
Also, biochemical analysis showed that neuroprotective ef-
fect of B com was not mediated by lowering plasma ho-
mocysteine. The present study showed that using B com
reduces the level of MDA in the brain rats treated with 6-
OHDA. Therefore, antiparkinsonian and neuroprotective
effects of B com were probably mediated by reduction of
oxidative stress. It was in agreement with several data
showing that B vitamins had antioxidant effects (22-34).
Several reports addressed the neuroprotective effect of
flu and Glib. Flu has cytoprotectant actions in neuronal
cultures (5, 8), chromaffin cell cultures (9), hippocampal
slices (10) and in animal models of stroke (11). Flu also sig-
nificantly reduces glutamate-induced neurotoxicity (35),
enhances functional recovery following sciatic nerve crush
lesion in rats (36) and improves the survival of grafted
dopaminergic neurons (37). The current study data clearly
Biotech Health Sci. 2016; 3(4):e38762. 5
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Figure 4. Motor performance of different groups of rats in rotarod test was examined in three consecutive days; two sessions a day. Since con and veh groups of rats showed
almost similar results, only data of veh group are shown. *, P < 0.05; **, P<0.01; ***, P < 0.001 compared to veh group; s, P < 0.05 compared to F and B com groups; Kruskall-Wallis
nonparametric test followed by Mann-Whitney U test; AUC, area under the curve; R1 - R6, sessions of the test; R1, first session and R6, last session.
show that neuroprotective effect of flu is not mediated
by inhibition or reduction of 6-OHDA-induced oxidative
stress. Flu blocks Na+ and Ca2+ channels and prevents
the overloading of the cell with Ca2+ under pathological
and ischemic conditions (6). The overload of Ca2+ plays
an important role in the progressive death of nerve cells
occurring in the cerebral injury and cerebrovascular dis-
eases such as stroke and trauma (38, 39). Also, it was re-
cently demonstrated that the accumulation of intracel-
lular sodium ions causes a rapid Ca2+ overload through
the reverse operation of the Na+/Ca2+ exchange mecha-
nism (6). Another explanation was reported by Qu et al..
They showed that 6-OHDA modulates electrophysiological
properties of SNpc dopaminergic neurons through activa-
tion of voltage gated calcium channels (VGCCs). Activa-
tion of these channels amplifies 6-OHDA-induced oxidative
stress by increasing Ca2+ entry from extracellular matrix
and accelerates cell death (40).
Regarding Glib, Lee et al. showed that Glib attenu-
ates the cytotoxicity of MPP+ in PC12 cells by suppress-
ing changes in the mitochondrial membrane permeabil-
ity (18). Kim et al. reported that centrally administration
of sulfonylureas exerts a neuroprotective effect against
kainic acid (KA)-induced hippocampal CA3 neuronal death
(17). Also, studies on the midbrain DA neurons indicate
that blockade of KATP channels protects these neurons
against neurodegenerative agents (19, 20). Several mech-
anisms are suggested for neuroprotective effect of Glib. It
is reported that Glib prevents the activation of endothelial
caspase-3 through inhibition of the sulfonylurea receptors
(SUR) 1-regulated NC (Ca-ATP) channels. Caspase-3 activa-
tion is described as a major cause of apoptotic processes
(41). Glib also suppresses the inflammatory response, in-
cluding the expression of proinflammatory cytokines IL-
10 and TNF-α (42). The current study showed that Glib re-
duces oxidative stress and that antiparkinsonian effect of
Glib may be mediated by its suppressing effect on the ox-
idative stress. Glib might also have neuroprotective effect
by direct blocking of KATP channels. It is reported that
6-OHDA induces mitochondrial impairment and ATP defi-
ciency through inhibition of mitochondrial complexes I
and IV (31, 43, 44), which can cause neurodegeneration by
persistent activation of KATP channels.
In conclusion, the obtained data showed that combina-
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Figure 5. Malondialdehyde concentrations in blood (upper panel) and tissue sus-
pensions prepared from midbrain portion of the brain (lower panel) of rats. *, P <
0.05; **, P < 0.01 and ***, P < 0.001 compared to veh group; s, P < 0.05 and ss, P <
0.01 compared to G group; Kruskall-Wallis nonparametric test followed by Mann-
Whitney U test.
tion of flu, Glib and B com has antiparkinsonian effect in
6-OHDA animal model. This effect was significantly more
potent than antiparkinsonian effect of flu, Glib or B com
solely, suggesting a synergistic antiparkinsonian effect for
them. MDA measurement indicated that at least a part of
this effect was mediated through inhibition of oxidative
stress by B com and Glib. Flu, through the blockade of
Ca2+ and Na+ channels, inhibited Ca2+ overload and its in-
duced neurodegeneration. This mechanism probably po-
tentiated neuroprotective effect of B com and Glib. Also,
besides the inhibition of oxidative stress, Glib might in-
hibit 6-OHDA-induced neurodegeneration by preventing
the persistent activation of K ATP channels.
Acknowledgments
Authors wish to thank Dr. Jahanihashemi for statistical
analysis of data and Miss Ayda Faraj for her assistance in
stereotaxic surgery.
Footnote
Funding/Support: This work was supported by a grant-in
aid for scientific research from both cellular and molecu-
lar research center, Qazvin University of Medical Sciences,
Qazvin, Iran, and Iran national science foundation (INSF).
References
1. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany
nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s
disease. Exp Neurol. 2000;166(1):29–43. doi: 10.1006/exnr.2000.7489.
[PubMed: 11031081].
2. de Lau LM, Koudstaal PJ, van Meurs JB, Uitterlinden AG, Hofman
A, Breteler MM. Methylenetetrahydrofolate reductase C677T geno-
type and PD. Ann Neurol. 2005;57(6):927–30. doi: 10.1002/ana.20509.
[PubMed: 15929053].
3. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of
Parkinson’s disease. Neurology. 1996;47(6 Suppl 3):S161–70. [PubMed:
8959985].
4. Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, et
al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in
families with Parkinson disease. Arch Neurol. 2007;64(4):576–80. doi:
10.1001/archneur.64.4.576. [PubMed: 17420321].
5. Pauwels PJ, Leysen JE, Janssen PA. Ca++ and Na+ channels in-
volved in neuronal cell death. Protection by flunarizine. Life Sci.
1991;48(20):1881–93. [PubMed: 1850815].
6. Annoura H, Nakanishi K, Uesugi M, Fukunaga A, Imajo S, Miyajima
A, et al. Synthesis and biological evaluation of new 4-arylpiperidines
and 4-aryl-4-piperidinols: dual Na(+) and Ca(2+) channel blockers
with reduced affinity for dopamine D(2) receptors. Bioorg Med Chem.
2002;10(2):371–83. [PubMed: 11741786].
7. van Zwieten PA. Calcium antagonists, calcium entry blockers and cal-
cium overload blockers; nomenclature and classification [in Dutch].
Ned Tijdschr Geneeskd. 1985;129(17):777–80. [PubMed: 2582280].
8. Rich KM, Hollowell JP. Flunarizine protects neurons from death af-
ter axotomy or NGF deprivation. Science. 1990;248(4961):1419–21.
[PubMed: 2356470].
9. Maroto R, De la Fuente MT, Artalejo AR, Abad F, Lopez MG, Garcia-
Sancho J, et al. Effects of Ca2+ channel antagonists on chromaffin cell
death and cytosolic Ca2+ oscillations induced by veratridine. Eur J
Pharmacol. 1994;270(4):331–9. [PubMed: 7805782].
10. Ashton D, Willems R, Marrannes R, Janssen PA. Extracellular ions
during veratridine-induced neurotoxicity in hippocampal slices:
neuroprotective effects of flunarizine and tetrodotoxin. Brain Res.
1990;528(2):212–22. [PubMed: 2271923].
11. De Ryck M, Van Reempts J, Borgers M, Wauquier A, Janssen PA. Photo-
chemical stroke model: flunarizine prevents sensorimotor deficits af-
ter neocortical infarcts in rats. Stroke. 1989;20(10):1383–90. [PubMed:
2799870].
12. Miki T, Liss B, Minami K, Shiuchi T, Saraya A, Kashima Y, et al. ATP-
sensitive K+ channels in the hypothalamus are essential for the main-
tenance of glucose homeostasis. Nat Neurosci. 2001;4(5):507–12. doi:
10.1038/87455. [PubMed: 11319559].
13. Wang S, Hu LF, Yang Y, Ding JH, Hu G. Studies of ATP-sensitive
potassium channels on 6-hydroxydopamine and haloperidol
rat models of Parkinson’s disease: implications for treating
Parkinson’s disease?. Neuropharmacology. 2005;48(7):984–92. doi:
10.1016/j.neuropharm.2005.01.009. [PubMed: 15857625].
Biotech Health Sci. 2016; 3(4):e38762. 7
Sarookhani MR et al.
14. Kou J, Klorig DC, Bloomquist JR. Potentiating effect of the ATP-
sensitive potassium channel blocker glibenclamide on complex
I inhibitor neurotoxicity in vitro and in vivo. Neurotoxicology.
2006;27(5):826–34. doi: 10.1016/j.neuro.2006.04.004. [PubMed:
16725203].
15. McGroarty A, Greenfield SA. Blockade of dopamine storage, but
not of dopamine synthesis, prevents activation of a tolbutamide-
sensitive K+ channel in the guinea-pig substantia nigra. Exp Brain Res.
1996;110(3):360–6. [PubMed: 8871095].
16. Busija DW, Lacza Z, Rajapakse N, Shimizu K, Kis B, Bari F, et al. Targeting
mitochondrial ATP-sensitive potassium channels–a novel approach
to neuroprotection. Brain Res Brain Res Rev. 2004;46(3):282–94. doi:
10.1016/j.brainresrev.2004.06.011. [PubMed: 15571770].
17. Kim CH, Park SH, Sim YB, Kim SS, Kim SJ, Lim SM, et al. Effect of
tolbutamide, glyburide and glipizide administered supraspinally
on CA3 hippocampal neuronal cell death and hyperglycemia in-
duced by kainic acid in mice. Brain Res. 2014;1564:33–40. doi:
10.1016/j.brainres.2014.03.046. [PubMed: 24713348].
18. Lee CS, Kim YJ, Ko HH, Han ES. Inhibition of 1-methyl-4-
phenylpyridinium-induced mitochondrial dysfunction and cell
death in PC12 cells by sulfonylurea glibenclamide. Eur J Pharmacol.
2005;527(1-3):23–30. doi: 10.1016/j.ejphar.2005.10.008. [PubMed:
16310184].
19. Toulorge D, Guerreiro S, Hirsch EC, Michel PP. KATP channel block-
ade protects midbrain dopamine neurons by repressing a glia-to-
neuron signaling cascade that ultimately disrupts mitochondrial cal-
cium homeostasis. J Neurochem. 2010;114(2):553–64. doi: 10.1111/j.1471-
4159.2010.06785.x. [PubMed: 20456014].
20. Rodriguez-Pallares J, Parga JA, Joglar B, Guerra MJ, Labandeira-
Garcia JL. Mitochondrial ATP-sensitive potassium channels en-
hance angiotensin-induced oxidative damage and dopaminergic
neuron degeneration. Relevance for aging-associated suscepti-
bility to Parkinson’s disease. Age (Dordr). 2012;34(4):863–80. doi:
10.1007/s11357-011-9284-7. [PubMed: 21713375].
21. Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L,
et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates
cerebral edema after ischemic stroke. Nat Med. 2006;12(4):433–40.
doi: 10.1038/nm1390. [PubMed: 16550187].
22. Jia H, Liu Z, Li X, Feng Z, Hao J, Li X, et al. Synergistic anti-
Parkinsonism activity of high doses of B vitamins in a
chronic cellular model. Neurobiol Aging. 2010;31(4):636–46. doi:
10.1016/j.neurobiolaging.2008.05.031. [PubMed: 18639366].
23. Haghdoost-Yazdi H, Sarookhani M, Faraj A, Fraidouni N, Dar-
gahi T, Yaghoubidoust MH, et al. Evaluation of the association
between blood homocysteine concentration and the degree of
behavioral symptoms in the 6-hydroxydopamine-induced Parkin-
sonism in rat. Pharmacol Biochem Behav. 2014;124:297–304. doi:
10.1016/j.pbb.2014.06.020. [PubMed: 24992727].
24. Haghdoost-Yazdi H, Fraidouni N, Faraji A, Jahanihashemi H, Sa-
rookhani M. High intake of folic acid or complex of B vitamins pro-
vides anti-Parkinsonism effect: no role for serum level of homocys-
teine.Behav Brain Res. 2012;233(2):375–81. doi: 10.1016/j.bbr.2012.05.011.
[PubMed: 22610053].
25. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San
Diego CA: Academic Press; 2007.
26. Fujita M, Nishino H, Kumazaki M, Shimada S, Tohyama M, Nishimura
T. Expression of dopamine transporter mRNA and its binding site in
fetal nigral cells transplanted into the striatum of 6-OHDA lesioned
rat. Brain Res Mol Brain Res. 1996;39(1-2):127–36. [PubMed: 8804721].
27. Borlongan CV, Sanberg PR. Elevated body swing test: a new behavioral
parameter for rats with 6-hydroxydopamine-induced hemiparkin-
sonism. J Neurosci. 1995;15(7 Pt 2):5372–8. [PubMed: 7623159].
28. Albro PW, Corbett JT, Schroeder JL. Application of the thiobarbitu-
rate assay to the measurement of lipid peroxidation products in
microsomes. J Biochem Biophys Methods. 1986;13(3):185–94. [PubMed:
3782721].
29. Shimohama S, Sawada H, Kitamura Y, Taniguchi T. Disease model:
Parkinson’s disease. Trends Mol Med. 2003;9(8):360–5. [PubMed:
12928038].
30. Yuan H, Sarre S, Ebinger G, Michotte Y. Histological, behavioural
and neurochemical evaluation of medial forebrain bundle and stri-
atal 6-OHDA lesions as rat models of Parkinson’s disease. J Neurosci
Methods. 2005;144(1):35–45. doi: 10.1016/j.jneumeth.2004.10.004.
[PubMed: 15848237].
31. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and mod-
els. Neuron. 2003;39(6):889–909. [PubMed: 12971891].
32. Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characteriza-
tion of a unilateral 6-OHDA-lesion model of Parkinson’s disease in
mice. Behav Brain Res. 2005;162(1):1–10. doi: 10.1016/j.bbr.2005.02.023.
[PubMed: 15922062].
33. Abrous DN, Rodriguez JJ, Montaron MF, Aurousseau C, Le Moal M, Bar-
neoud P. Behavioural recovery after unilateral lesion of the dopamin-
ergic mesotelencephalic pathway: effect of repeated testing. Neuro-
science. 1998;84(1):213–21. [PubMed: 9522375].
34. Chen TF, Chiu MJ, Huang CT, Tang MC, Wang SJ, Wang CC, et al.
Changes in dietary folate intake differentially affect oxidised lipid
and mitochondrial DNA damage in various brain regions of rats
in the absence/presence of intracerebroventricularly injected amy-
loid beta-peptide challenge. Br J Nutr. 2011;105(9):1294–302. doi:
10.1017/S0007114510005052. [PubMed: 21208488].
35. Toriu N, Akaike A, Yasuyoshi H, Zhang S, Kashii S, Honda Y, et al. Lom-
erizine, a Ca2+ channel blocker, reduces glutamate-induced neuro-
toxicity and ischemia/reperfusion damage in rat retina. Exp Eye Res.
2000;70(4):475–84. doi: 10.1006/exer.1999.0809. [PubMed: 10865996].
36. Patro IK, Chattopadhyay M, Patro N. Flunarizine enhances functional
recovery following sciatic nerve crush lesion in rats. Neurosci Lett.
1999;263(2-3):97–100. [PubMed: 10213144].
37. Kaminski Schierle GS, Hansson O, Brundin P. Flunarizine im-
proves the survival of grafted dopaminergic neurons. Neuroscience.
1999;94(1):17–20. [PubMed: 10613492].
38. Diaz-Prieto N, Herrera-Peco I, de Diego AM, Ruiz-Nuno A, Gallego-
Sandin S, Lopez MG, et al. Bcl2 mitigates Ca2+ entry and mito-
chondrial Ca2+ overload through downregulation of L-type
Ca2+ channels in PC12 cells. Cell Calcium. 2008;44(4):339–52. doi:
10.1016/j.ceca.2008.01.007. [PubMed: 18346784].
39. Cano-Abad MF, Villarroya M, Garcia AG, Gabilan NH, Lopez MG.
Calcium entry through L-type calcium channels causes mito-
chondrial disruption and chromaffin cell death. J Biol Chem.
2001;276(43):39695–704. doi: 10.1074/jbc.M102334200. [PubMed:
11500491].
40. Qu L, Wang Y, Zhang HT, Li N, Wang Q, Yang Q, et al. 6-OHDA
induced calcium influx through N-type calcium channel alters
membrane properties via PKA pathway in substantia nigra pars
compacta dopaminergic neurons. Neurosci Lett. 2014;575:1–6. doi:
10.1016/j.neulet.2014.05.038. [PubMed: 24861516].
41. Simard JM, Geng Z, Woo SK, Ivanova S, Tosun C, Melnichenko L,
et al. Glibenclamide reduces inflammation, vasogenic edema, and
caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood
FlowMetab. 2009;29(2):317–30. doi: 10.1038/jcbfm.2008.120. [PubMed:
18854840].
42. Wali B, Ishrat T, Atif F, Hua F, Stein DG, Sayeed I. Glibenclamide Admin-
istration Attenuates Infarct Volume, Hemispheric Swelling, and Func-
tional Impairments following Permanent Focal Cerebral Ischemia in
Rats. Stroke Res Treat. 2012;2012:460909. doi: 10.1155/2012/460909.
[PubMed: 22988544].
43. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munoz-Patino
AM, Labandeira-Garcia JL. Autoxidation and neurotoxicity of 6-
hydroxydopamine in the presence of some antioxidants: potential
implication in relation to the pathogenesis of Parkinson’s disease. J
Neurochem. 2000;74(4):1605–12. [PubMed: 10737618].
44. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, et
8 Biotech Health Sci. 2016; 3(4):e38762.
Sarookhani MR et al.
al. Molecular pathways involved in the neurotoxicity of 6-OHDA,
dopamine and MPTP: contribution to the apoptotic theory in Parkin-
son’s disease. Prog Neurobiol. 2001;65(2):135–72. [PubMed: 11403877].
Biotech Health Sci. 2016; 3(4):e38762. 9
